Long-term follow-up of tacrolimus treatment in immune posterior uveitis

European Journal of Ophthalmology

Volumn 17, Issue 1, 2007, Pages 69-74

  Figueroa, Marta S ^a,b   Ciancas, E ^a,b   Orte, L ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b VISSUM Corporacion Oftalmologica   (Spain)

Author keywords

Immune uveitis; Posterior uveitis; Tacrolimus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACNE; ADULT; ARTICLE; BREAST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; HAIR LOSS; HAND TREMOR; HEADACHE; HUMAN; HYPERTENSION; IMMUNE POSTERIOR UVEITIS; KIDNEY FUNCTION; LONG TERM CARE; LOW DRUG DOSE; MALE; MAMMARY TURGIDITY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; TREATMENT DURATION; UVEITIS; VISUAL ACUITY; BIOAVAILABILITY; BLOOD; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; BIOLOGICAL AVAILABILITY; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TACROLIMUS; TREATMENT OUTCOME; UVEITIS, POSTERIOR; VISUAL ACUITY;

EID: 34047272829     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210701700110     Document Type: Article

References (11)

1. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718-26.
2. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-7.
3. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998; 6: 101-9.
4. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993; 115: 763-9.
5. Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998; 30: 1240-2.
6. Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994; 118: 723-9.
7. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999; 106: 723-8.
8. Ben Erza, Forrester JV. Uveitis scoring system. Berlin: Springer-Verlag, 1991; 1-13.
9. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine and FK 506. Immunol Today 1992; 13: 136-41.
10. Mochizuki M, Ikeda E, Shirao M, Fujito S, Yoshimura K, Shimada N. Preclinical and clinical study of FK506 in uveitis. Curr Eye Res 1992; 11 (Suppl): S87-95.
11. Murphy C, Greiner K, Plskova J. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005; 123: 634-41.